Floatz logo

Safusidenib

Astrocytoma, IDH-Mutant, Grade 4

Nuvation Bio Inc.Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Astrocytoma, IDH-Mutant, Grade 4 cohort.

Asset / SponsorPhaseRating
Nivolumab
Andrew P. Groves
Phase 2B
gi-102
Mayo Clinic
Phase 2CCC
Pembrolizumab
Mayo Clinic
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Eflornithine
Mayo Clinic
Phase 1/2CC

View all 15 →

Same molecule, other indications

Safusidenib is also rated in:

glioblastomaDormant
B
Indicative ·
60 / 100
View asset →
astrocytoma, IDH-mutant, grade 3Dormant
B
Indicative ·
60 / 100
View asset →
astrocytoma, IDH-mutant, grade 2Dormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →